1. European Medicines Agency.Committee for Medical Products for Human use Core SPC for Human Tetanus Immunoglobulin for intramuscular use. CPMP/BPWG/3730/02.2006[cited 2023 Jul 7]. Available from:https://www.ema.europa.eu/en/core-summary-product-characteristics-human-tetanus-immunoglobulin-intramuscular-use
2. Robert Koch Institute.Tetanus RKI‐Ratgeber.2018[cited 2023 Jul 7]. Available from:https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Tetanus.html;jsessionid=390A4F781973A18F0D42699C65BA4BA4.internet072#doc2398266bodyText10
3. Public Health England.Tetanus. Guidance on the management of suspected tetanus cases and on the assessment and management of tetanus‐prone wounds.2019[cited 2023 Jul 7]. Available from:https://www.gov.uk/government/publications/tetanus‐advice‐for‐health‐professionals
4. Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations